Elephas Raises $40 Million in Series B-2 to Advance Commercialization of Live Tumor Profiling Platform

Reinvestment from existing backers underscores confidence in Elephas' predictive approach to improving immunotherapy treatment response rates Elephas B...

November 07, 2025 | Friday | News
Santhera Closes USD 13 Million Royalty Monetization Agreement to Support AGAMREE® Global Launches

 Santhera Pharmaceuticals (SIX: SANN) announces the closing of a USD 13 million royalty monetization agreement, first announced in September 2025, t...

November 06, 2025 | Thursday | News
Jupiter Neurosciences Secures Up to $20 Million in Flexible Financing from Yorkville Advisors to Advance Parkinson’s Trial and Nugevia™ Expansion

Financing designed to support Phase 2 Parkinson’s trial and accelerate Nugevia™ product line growth Jupiter Neurosciences, Inc , a clinical...

October 28, 2025 | Tuesday | News
Minerva Neurosciences Secures up to $200 Million to Advance Roluperidone Through Confirmatory Phase 3 Trial and NDA Resubmission

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have ...

October 22, 2025 | Wednesday | News
Rani Therapeutics Enters $1 Billion Collaboration with Chugai for Oral Biologics Development

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $10...

October 20, 2025 | Monday | News
Propanc Biopharma Enters Strategic $100M Financing Agreement with Hexstone Capital

Propanc Biopharma, Inc. ("Propanc" or the "Company") is pleased to announce it has entered into a strategic financing agreement of up to $100 million wit...

October 16, 2025 | Thursday | News
The 2025 Biopharma Index: Stocks Set to Outperform in a Post-AI Market

The biopharmaceutical industry enters 2025 on strong footing, bolstered by scientific breakthroughs and a wave of digital innovation. In the post-AI market...

October 10, 2025 | Friday | Analysis
Esperion Secures Key Patent Settlement with Dr. Reddy’s, Protecting NEXLETOL and NEXLIZET Until 2040

Esperion announced that it has entered into a settlement agreement with Dr. Reddy’s Laboratories, Inc. and its affiliate Dr. Reddy’s Laborato...

October 06, 2025 | Monday | News
POP Biotechnologies Secures $2.46M NIH Grant to Advance “Mosaic” Immunotherapy for Alzheimer’s

POP Biotechnologies, Inc. (POP BIO), has been awarded a $2.46M USD grant by the National Institutes of Health (NIH) to pursue development of a “mos...

October 02, 2025 | Thursday | News
Barinthus Bio and Clywedog Therapeutics Announce Definitive Merger Agreement to Create Nasdaq-Listed Clywedog Therapeutics, Inc.

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...

October 01, 2025 | Wednesday | News
Harrow to Acquire Melt Pharmaceuticals, Advancing Non-Opioid, Needle-Free Sedation Therapy MELT-300

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into an ag...

September 30, 2025 | Tuesday | News
Sanofi Ventures Secures $625M Boost, Expanding Assets to $1.4B

The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging...

September 25, 2025 | Thursday | News
Pierre Boulud Credits GO∙28 Plan as bioMérieux Delivers Strong Profitability in H1 2025

  Pierre Boulud, Chief Executive Officer of bioMérieux, set the tone for the company’s first-half 2025 performance: “With a stron...

September 16, 2025 | Tuesday | Company results
IFF Expands LMR Naturals Site in Grasse with €10 Million Investment to Drive Next-Generation Natural Ingredient Innovation

-IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and biosciences,  inaugurated its expanded LMR Naturals site in Grasse fo...

September 09, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close